{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:17Z","timestamp":1778843357102,"version":"3.51.4"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.ARUMS.REC.1398.218"],"award-info":[{"award-number":["IR.ARUMS.REC.1398.218"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.ARUMS.REC"],"award-info":[{"award-number":["IR.ARUMS.REC"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["1398.218"],"award-info":[{"award-number":["1398.218"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.msard.2023.104622","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T03:31:31Z","timestamp":1678937491000},"page":"104622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In silico repurposing of CNS drugs for multiple sclerosis"],"prefix":"10.1016","volume":"73","author":[{"given":"Elham","family":"Sardari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Ebadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-2497","authenticated-orcid":false,"given":"Nima","family":"Razzaghi-Asl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104622_bib0001","doi-asserted-by":"crossref","first-page":"12777","DOI":"10.1038\/ncomms12777","article-title":"Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities","volume":"7","author":"Ahmed-Belkacem","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2023.104622_bib0002","doi-asserted-by":"crossref","unstructured":"Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., Hermans J., 1981. Interaction Models For Water in Relation to Protein Hydration. In: Pullman B., Ed., Intermolecular Forces, D. Reidel Publishing Company, Dordrecht, 331\u2013342.","DOI":"10.1007\/978-94-015-7658-1_21"},{"issue":"5","key":"10.1016\/j.msard.2023.104622_bib0003","article-title":"Daclizumab therapy for multiple sclerosis. cold spring harb","volume":"9","author":"Bielekova","year":"2019","journal-title":"Perspect. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104622_bib0004","doi-asserted-by":"crossref","first-page":"e59630","DOI":"10.1371\/journal.pone.0059630","article-title":"Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis","volume":"8","author":"Billich","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.msard.2023.104622_bib0005","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.msard.2023.104622_bib0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/j100785a001","article-title":"Van der Waals volumes and Radii","volume":"68","author":"Bondi","year":"1964","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.msard.2023.104622_bib0007","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.msard.2023.104622_bib0008","article-title":"Filling the gap in CNS drug development: evaluation of the role of drug repurposing","volume":"5","author":"Caban","year":"2017","journal-title":"J. Mark. Access Heal. Policy"},{"key":"10.1016\/j.msard.2023.104622_bib0009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","article-title":"Cost-effectiveness of Alemtuzumab in the treatment of relapsing forms of Multiple Sclerosis in the United States","volume":"22","author":"Chirikov","year":"2019","journal-title":"Value Heal."},{"key":"10.1016\/j.msard.2023.104622_bib0010","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.msard.2023.104622_bib0011","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/jp110373f","article-title":"Conformational relaxation and water penetration coupled to ionization of internal groups in proteins","volume":"115","author":"Damjanovi\u0107","year":"2011","journal-title":"J. Phys. Chem. A."},{"key":"10.1016\/j.msard.2023.104622_bib0012","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.msard.2023.104622_bib0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci."},{"issue":"6","key":"10.1016\/j.msard.2023.104622_bib0014","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3892\/br.2022.1579","article-title":"Multiple sclerosis and computational biology (Review)","volume":"17","author":"Diakou","year":"2022","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.msard.2023.104622_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.immuni.2020.03.013","article-title":"Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity","volume":"52","author":"DiToro","year":"2020","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.msard.2023.104622_bib0016","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.msard.2023.104622_bib0017","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.biocel.2010.01.004","article-title":"Mitochondrial medicine for neurodegenerative diseases","volume":"42","author":"Du","year":"2016","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"10.1016\/j.msard.2023.104622_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2010.01.001","article-title":"Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation","volume":"20","author":"Esposito","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104622_bib0019","series-title":"Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection","first-page":"125","article-title":"Neuroprotective features of Hsp90 inhibitors exhibiting anti-inflammatory actions: implications for multiple sclerosis","author":"Feinstein","year":"2008"},{"key":"10.1016\/j.msard.2023.104622_bib0020","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1073\/pnas.0702228104","article-title":"Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis","volume":"104","author":"Forte","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.msard.2023.104622_bib0021","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.msard.2023.104622_bib0022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J. Clin. Cases"},{"issue":"1","key":"10.1016\/j.msard.2023.104622_bib0023","first-page":"1","article-title":"Multiple Sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"issue":"D1","key":"10.1016\/j.msard.2023.104622_bib0024","doi-asserted-by":"crossref","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","article-title":"The reactome pathway knowledgebase 2022","volume":"50","author":"Gillespie","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.msard.2023.104622_bib0025","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104622_bib0026","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/13543784.2019.1676725","article-title":"Siponimod in the treatment of multiple sclerosis","volume":"12","author":"Goodman","year":"2019","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.msard.2023.104622_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126717","article-title":"Discovery of novel cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies","volume":"29","author":"Gr\u00e4dler","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.msard.2023.104622_bib0028","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1365-2567.1998.00434.x","article-title":"Emigration of mature T cells from the thymus is inhibited by the imidazole-based compound 2-acetyl-4-tetrahydroxybutylimidazole","volume":"93","author":"Gugasyan","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2023.104622_bib0029","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.msard.2023.104622_bib0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.194.5.669","article-title":"A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis","volume":"194","author":"Huseby","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2023.104622_bib0031","article-title":"The transitional phase of multiple sclerosis: characterization and conceptual framework","volume":"44","author":"KleiterabIlya","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.104622_bib0032","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4103\/1673-5374.235242","article-title":"Drug repurposing for neuroregeneration in multiple sclerosis","volume":"13","author":"K\u00fcry","year":"2018","journal-title":"Neural Regen. Res."},{"issue":"12","key":"10.1016\/j.msard.2023.104622_bib0033","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1177\/1352458517729455","article-title":"Targets of therapy in progressive MS","volume":"23","author":"Lassmann","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104622_bib0034","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/157489312803901009","article-title":"Steered molecular dynamics - a promising tool for drug design","volume":"7","author":"Li","year":"2012","journal-title":"Curr. Bioinform."},{"key":"10.1016\/j.msard.2023.104622_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2019.04.035","article-title":"Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg\/Th17 in a mouse model","volume":"705","author":"Li","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.msard.2023.104622_bib0036","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood-brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.msard.2023.104622_bib0037","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.msard.2023.104622_bib0038","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.drudis.2016.05.018","article-title":"In vitro and ex vivo models of multiple sclerosis","volume":"21","author":"Madill","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.msard.2023.104622_bib0039","first-page":"97","article-title":"Repurposing dopaminergic drugs for MS - the evidence mounts","volume":"292","author":"Marino","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"6972","key":"10.1016\/j.msard.2023.104622_bib0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.msard.2023.104622_bib0041","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2023.104622_bib0042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/npp.2008.145","article-title":"In vitro and in vivo pharmacological models to assess demyelination and remyelination","volume":"34","author":"Merrill","year":"2009","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.msard.2023.104622_bib0043","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/pharmaceutics11090446","article-title":"Computational drug repurposing algorithm targeting TRPA1 calcium channel as a potential therapeutic solution for Multiple Sclerosis","volume":"11","author":"Mihai","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.msard.2023.104622_bib0044","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"14","key":"10.1016\/j.msard.2023.104622_bib0045","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.febslet.2014.05.006","article-title":"Forces stabilizing proteins","volume":"588","author":"Nick Pace","year":"2014","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.msard.2023.104622_bib0046","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1212\/CON.0000000000000725","article-title":"Multiple Sclerosis risk factors and pathogenesis","volume":"25","author":"Nourbakhsh","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.msard.2023.104622_bib0047","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10629360903560637","article-title":"Analysis of hydrophobic interactions of antagonists with the beta2-adrenergic receptor","volume":"21","author":"Novoseletsky","year":"2010","journal-title":"SAR QSAR Environ. Res."},{"issue":"10","key":"10.1016\/j.msard.2023.104622_bib0048","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jocn.2014.01.009","article-title":"Smoking increases the risk of multiple sclerosis in Queensland","volume":"21","author":"O'Gorman","year":"2014","journal-title":"Australia. J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2023.104622_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1602\/neurorx.2.1.1","article-title":"The blood-brain barrier and neurotherapeutics","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"1","key":"10.1016\/j.msard.2023.104622_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.msard.2023.104622_bib0051","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"key":"10.1016\/j.msard.2023.104622_bib0052","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41589-022-01116-1","article-title":"Discovery and molecular basis of subtype-selective cyclophilin inhibitors","volume":"18","author":"Peterson","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.msard.2023.104622_bib0053","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104622_bib0054","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.3168","article-title":"Animal models of multiple sclerosis: the good, the bad and the bottom line","volume":"15","author":"Ransohoff","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.msard.2023.104622_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108039","article-title":"Identification of potential antileishmanial agents via structure-based molecular simulations","volume":"110","author":"Razzaghi-Asl","year":"2022","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.msard.2023.104622_bib0056","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jmgm.2018.05.010","article-title":"Identification of COX-2 inhibitors via structure-based virtual screening and molecular dynamics simulation","volume":"83","author":"Razzaghi-Asl","year":"2018","journal-title":"J. Mol. Graph. Model."},{"issue":"W1","key":"10.1016\/j.msard.2023.104622_bib0057","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.msard.2023.104622_bib0058","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3389\/fphar.2018.00923","article-title":"Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview","volume":"9","author":"Salmaso","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2023.104622_bib0059","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"17","author":"Sanner","year":"1999","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.msard.2023.104622_bib0060","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: a tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"Schuttelkopf","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.msard.2023.104622_bib0061","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.msard.2023.104622_bib0062","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.msard.2023.104622_bib0063","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/ijms24020985","article-title":"In silico drug repurposing in multiple Sclerosis using scRNA-Seq data","volume":"24","author":"Shevtsov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 6","key":"10.1016\/j.msard.2023.104622_bib0064","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12911-022-02034-x","article-title":"In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim","volume":"22","author":"Sips","year":"2022","journal-title":"BMC Med. Inform. Decis. Mak."},{"issue":"2","key":"10.1016\/j.msard.2023.104622_bib0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of multiple sclerosis","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin. Neurol."},{"issue":"9\u201310","key":"10.1016\/j.msard.2023.104622_bib0066","first-page":"293","article-title":"Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis","volume":"66","author":"Speer","year":"2013","journal-title":"Ideggyogy Sz"},{"key":"10.1016\/j.msard.2023.104622_bib0067","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.msard.2023.104622_bib0068","article-title":"Multiple sclerosis and drug discovery: a work of translation","volume":"68","author":"'t Hart","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2023.104622_bib0069","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4939-8630-9_3","article-title":"In silico drug design: non-peptide mimetics for the immunotherapy of multiple sclerosis","volume":"1824","author":"Tzoupis","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.msard.2023.104622_bib0070","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/187152712801661284","article-title":"In vitro and in vivo models of multiple sclerosis","volume":"11","author":"van der Star","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"4","key":"10.1016\/j.msard.2023.104622_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117705","article-title":"Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive Multiple Sclerosis","volume":"10","author":"Vesterinen","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2023.104622_bib0072","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1074\/jbc.M115.700385","article-title":"Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental Multiple Sclerosis","volume":"291","author":"Warne","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2023.104622_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724718","article-title":"Progress in the application of drugs for the treatment of multiple sclerosis","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2023.104622_bib0074","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1021\/jm500338n","article-title":"Orally active 7\u2011substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1\u2011phosphate lyase for the treatment of Multiple Sclerosis","volume":"57","author":"Weiler","year":"2014","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.msard.2023.104622_bib0075","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.msard.2023.104622_bib0076","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2023.104622_bib0077","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4103\/1673-5374.353495","article-title":"Cyclophilin d-induced mitochondrial impairment confers axonal injury after intracerebral hemorrhage in mice","volume":"18","author":"Yang","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"11","key":"10.1016\/j.msard.2023.104622_bib0078","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/aje\/152.11.1056","article-title":"Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women","volume":"152","author":"Zhang","year":"2000","journal-title":"Am. J. Epidemiol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:33Z","timestamp":1778840913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":78,"alternative-id":["S2211034823001268"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104622","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico repurposing of CNS drugs for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104622"}}